Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing
Brief: Oragenics Announces Strategic Partnership With Receptor.AI To Accelerate Pipeline Development
Oragenics tumbles after $20 million public offering
Brief: Oragenics Announces Health And Disability Ethics Committee Submission
Brief: Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress
Brief: Oragenics Effective Dec 16, Terminated Employment Of J. Michael Redmond, Co's Interim Principal Executive Officer And President
Brief: Oragenics Says Co Entered Into At-The-Market Sales Agreement With Dawson James Securities
Brief: Oragenics Updates Shareholders On Concussion Drug Progress
Brief: Oragenics Announces Closing Of Public Offering
Brief: Oragenics Prices Public Offering At $0.55 Per Share
Brief: Oragenics Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
Brief: Oragenics Provides Update On Drug Intended To Treat Concussion
Brief: Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Brief: Oragenics Announces Pricing Of Public Offering
Brief: Oragenics Announces NYSE American Acceptance Of Plan Of Compliance
Brief: Oragenics Appoints William “Frank” Peacock MD As Chief Clinical Officer